Evidence map›Paper›PMID 24918054›Full record

ArticleFEBS open bio2014

Changed membrane integration and catalytic site conformation are two mechanisms behind the increased Aβ42/Aβ40 ratio by presenilin 1 familial Alzheimer-linked mutations.

Johanna Wanngren, Patricia Lara, Karin Ojemalm, Silvia Maioli, Nasim Moradi, Lu Chen, Lars O Tjernberg, Johan Lundkvist, IngMarie Nilsson, Helena Karlström

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Towards a Unitary Hypothesis of Alzheimer's Disease Pathogenesis.Journal of Alzheimer's disease : JAD · 2024
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Johanna WanngrenDepartment of NVS, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden.
Patricia LaraDepartment of Biochemistry & Biophysics, Stockholm University, Stockholm, Sweden.
Karin OjemalmDepartment of Biochemistry & Biophysics, Stockholm University, Stockholm, Sweden.
Silvia MaioliDepartment of NVS, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden.
Nasim MoradiDepartment of Biochemistry & Biophysics, Stockholm University, Stockholm, Sweden.
Lu ChenDepartment of Biochemistry & Biophysics, Stockholm University, Stockholm, Sweden.
Lars O TjernbergDepartment of NVS, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden.
Johan LundkvistAlzeCure, Karolinska Institutet, Stockholm, Sweden.
IngMarie NilssonDepartment of Biochemistry & Biophysics, Stockholm University, Stockholm, Sweden.
Helena KarlströmDepartment of NVS, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SEStockholm University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The enzyme complex γ-secretase generates amyloid β-peptide (Aβ), a 37-43-residue peptide associated with Alzheimer disease (AD). Mutations in presenilin 1 (PS1), the catalytical subunit of γ-secretase, result in familial AD (FAD). A unifying theme among FAD mutations is an alteration in the ratio Aβ species produced (the Aβ42/Aβ40 ratio), but the molecular mechanisms responsible remain elusive. In this report we have studied the impact of several different PS1 FAD mutations on the integration of selected PS1 transmembrane domains and on PS1 active site conformation, and whether any effects translate to a particular amyloid precursor protein (APP) processing phenotype. Most mutations studied caused an increase in the Aβ42/Aβ40 ratio, but via different mechanisms. The mutations that caused a particular large increase in the Aβ42/Aβ40 ratio did also display an impaired APP intracellular domain (AICD) formation and a lower total Aβ production. Interestingly, seven mutations close to the catalytic site caused a severely impaired integration of proximal transmembrane/hydrophobic sequences into the membrane. This structural defect did not correlate to a particular APP processing phenotype. Six selected FAD mutations, all of which exhibited different APP processing profiles and impact on PS1 transmembrane domain integration, were found to display an altered active site conformation. Combined, our data suggest that FAD mutations affect the PS1 structure and active site differently, resulting in several complex APP processing phenotypes, where the most aggressive mutations in terms of increased Aβ42/Aβ40 ratio are associated with a decrease in total γ-secretase activity.

Indexed as

AD, Alzheimer diseaseAICD, amyloid precursor protein intracellular domainAlzheimer diseaseAmyloid β-peptideAPP, amyloid precursor proteinAβ, amyloid-β peptideBD8, blastocyst-derived embryonic stem cellsBis-Tris, 2-(bis(2-hydroxyethyl)amino)-2-(hydroxymethyl)propane-1,3-diolCHAPSO, 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonic acidCRM, column-washed dog pancreas rough microsomesCTF, C-terminal fragmentEndo H, endoglycosidase HER, endoplasmic reticulumFAD, familial ADFLIM/FRET, Fluorescence Lifetime Imaging/ Fluorescence Resonance Energy TransferGCB, γ-secretase inhibitor coupled to biotinGVP, Gal4VP16Lep, leader peptidaseMembrane integrationMGD, minimal glycosylation distanceMSD, Meso Scale DiscoveryNTF, N-terminal fragmentProtein structurePS, presenilinRM, rough microsomesTMD, transmembrane domainsWT, wild typeγ-Secretase

Identifiers

PMID24918054
PMCPMC4050182
OpenAlexW2007543085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.